Zeus Capital has acted as nominated adviser and sole broker to 4d pharma on its AIM IPO and £16.5m institutional fundraise. On admission, 4d pharma had a market capitalisation of £36.5m
The company is a development-stage biopharmaceutical company focussed on developing new therapeutics that address unmet clinical needs. The company is targeting the development of platform technologies in new therapeutic areas. 4d pharma’s first project is the microbiome and the company intends to develop and bring to market a range of products to treat autoimmune diseases.
Dr Gary Waanders, Research Director at Zeus Capital, commented:
“We are proud to have been involved in the IPO of 4d pharma plc. The management team has substantial expertise and a solid track record of creating value for investors and the recognition of this was critical to the success of the fund raising. The first asset to be taken into clinical development promises to revolutionise the treatment of paediatric Crohn’s Disease, a severe gastrointestinal inflammatory disease in a small population of children. We look forward to following the progress of this and other developments at 4d pharma.”
Duncan Peyton, Chief Executive Officer at 4d pharma, commented:
“We are delighted to have completed the IPO and we thank Zeus for the management of the process on an accelerated timetable. 4d pharma received strong support from a group of blue-chip investors in the IPO and we look forward to the development of new classes of therapeutic products for the treatment of serious diseases.”